In this special Homerun Slides presentation, details of the CANTATA-D2 study are reviewed comparing the effects and benefits of the SGLT2 inhibitors and DPP-4 inhibitors…. To download in PowerPoint (.ppt) format: SGLT2 Inhibitors for Treatment of Type 2 Diabetes See more SGLT-2 Resources

Most of us who treat diabetes patients know that the hardest part is getting patients to make positive changes. We often set the targets so high that patients just give up. If you take a careful look at our Homerun Slides from Dr. Stanley Schwartz, you will see how small …

  In this week’s Homerun Slides, we discuss the Health Benefits of Modest Weight Loss; review some of the causes of the modern obesity crisis; and go over some of the Medical Consequences of Obesity….

Richard S. Beaser, MD This week’s excerpt covers the following questions: Which routine laboratory tests are recommended for type 2 diabetes patients? Which goals need to be established? Why should the word "diet" not be used to treat your type 2 patients? Should the primary focus be on weight loss? …

David Joffe, BSPharm, CDE  Brittany Davis, Pharm D Candidate, Presbyterian College School of Pharmacy The molecular mechanisms linking fatty acids to GLP-1 secretion from gut endocrine cells remain incompletely understood. Hirasawa and colleagues have identified a GPCR, designated GPR120 that serves as a receptor for fatty acids on gut endocrine cells. …

Exercise Log from dLife Print out copies of this simple daily exercise log from dLife and start charting your patients’ progress to help them set fitness goals. Exercise Log from dLife  

AliveCor® an EKG on Your Smart Phone  With the AliveCor System you can offer cardiac expertise to more of your patients, expanding the scope of your practice and providing valuable information about your patients’ cardiac health. The FDA has granted the company over-the-counter clearance for the AliveCor Heart Monitor, a …

FDA to Review Saxagliptin for Possible Heart Failure Risk More to come in next week’s issue.

Cyanidin and delphinidin, when encapsulated in nanoliposoms, decrease in vitro glycation of albumin and hemoglobin A. They also decrease blood glucose and blood cholesterol in diabetic mice. Iranian researchers investigated the effects of these materials in two forms of free and nanoliposomal on decreasing the damages caused by diabetes. Planta …

Oramed has submitted a protocol to the FDA to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes. The double-blind, randomized, placebo controlled, seven-day study design will be carried out at an inpatient setting on twenty-four type 1 diabetic patients. It’s hope …